1. In Vivo
  2. >>Deal-Making

Deals Shaping the Medical Industry, October 2016

 
• By Steven Muntner, Beth Allan, Maureen Riordan, Deanna Kamienski, and Amanda Micklus

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in September 2016.

Pharos Capital Group has taken a controlling interest in TechLab Inc. from Alere Inc. and TechLab's founders Dr. Tracy Wilkins and Dr. David Lyerly, both of whom will remain with the company and hold a minority stake. (Sep.)

Three members from Pharos Capital will join TechLab's board, while former Alere executive and TechLab board member Daniel Delaney takes the helm as CEO. Following the transaction, Alere will continue as the worldwide distributor of TechLab's products. TechLab develops rapid non-invasive diagnostics for gastrointestinal disease. Its Quik Chek technology enables accurate test results in less than a half hour. Applications for the company's diagnostics include C

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deal-Making

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

Dealmaking Quarterly Statistics, Q1 2025

 
• By Deanna Kamienski and Maureen Riordan

During Q1, biopharma M&A deal value reached $38.4bn and drew in $60.8bn in potential deal value from alliances. Device company M&A values reached $8.7bn.

Oncology’s Most Eligible Unpartnered Assets

 
• By Edwin Elmhirst

Evaluate's top five unpartnered clinical oncology assets reveals you have to get in early to snap up innovation in the competitive cancer space.

Deals In Depth: March 2025

 
• By Maureen Riordan

Eight $1bn+ alliances were penned in March, and five exceeded $2bn.

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.